 On the use of surrogate end points in randomized trialsC. B. Begg and D. H. Y. Leung Journal of the Royal Statistical Society Series A, 2000, vol. 163, issue 1, 15-28 Abstract: In a recent paper Day and Duffy proposed a strategy for designing a randomized trial of different breast cancer screening schedules. Their strategy was based on the use of predictors of mortality determined by patients' factors at diagnosis as surrogates for true mortality. On the basis of the Prentice criterion for validity of a surrogate end point, and data from earlier studies of breast cancer case survival, they showed that, not only would the trial require a much shorter follow‐up, but also that the information (i.e. inverse variance) for evaluating a treatment effect on mortality would be greater by a factor of nearly 3 if the predictors of mortality were used, compared with a trial in which mortality was actually observed. Although these results are technically correct, we believe that the conceptual strategy on which they are based is flawed, and that the fundamental problem is the Prentice criterion itself. In this paper the technical issues are discussed in detail, and an alternative structure for evaluating the validity of surrogate end points is proposed. Date: 2000 Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:bla:jorssa:v:163:y:2000:i:1:p:15-28 Ordering information: This journal article can be ordered from Access Statistics for this article Journal of the Royal Statistical Society Series A is currently edited by A. Chevalier and L. Sharples More articles in Journal of the Royal Statistical Society Series A from Royal Statistical Society Contact information at EDIRC. |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.